Naxos disease: A Patient Guide
At a Glance
Naxos disease is an inherited condition marked by woolly hair and thickened skin on the palms and soles, followed by a risk of heart muscle disease. Early cardiology follow-up, exercise limits, and family screening can help detect and manage heart involvement.
Naxos disease is a rare, inherited condition that acts as a bridge between the health of the skin and the strength of the heart. It is part of a group of conditions known as cardiocutaneous syndromes, where visible signs on the outside of the body provide critical clues about how the heart is functioning [1][2]. While a diagnosis can be daunting, the unique way Naxos disease progresses offers an opportunity to initiate cardiac surveillance before heart symptoms begin, though it does not guarantee the prevention of future issues [3][4].
This condition is defined by a specific “triad” of features that often appear in a sequence, though they are not always all present at the time of assessment. First, children are often born with or soon develop woolly hair, which is unusually tightly curled and sometimes fragile [1]. This is followed by palmoplantar keratoderma, a thickening of the skin on the palms of the hands and the soles of the feet that usually becomes noticeable as a child begins to crawl and walk [5]. The final part of the triad is arrhythmogenic cardiomyopathy, a heart condition where the muscle is gradually replaced by fibrous scar tissue and fat [2]. This structural change can interfere with the heart’s electrical system, potentially leading to irregular rhythms or a weakened pump over time [6].
The progression of Naxos disease is often age-dependent, meaning it changes as you grow. While the hair and skin features are usually present in early childhood, heart involvement typically does not become clinically apparent until adolescence or young adulthood [1][7]. Because the hair and skin signs are visible so early, they serve as a prompt for doctors to begin heart monitoring long before a teenager might experience palpitations, dizziness, or fainting [3][8]. This early window is the best time to build a specialized care team, including a cardiologist, dermatologist, and geneticist, to create a proactive plan for the years ahead [4].
Living with Naxos disease requires a focus on preservation and prevention. One of the most critical elements of management is exercise restriction. High-intensity, competitive, or endurance sports put immense mechanical strain on the heart muscle, which can trigger dangerous arrhythmias and accelerate the progression of the disease [9][10]. While low-intensity activity is often safe and encouraged, avoiding heavy exertion is a cornerstone of protecting heart function for those affected [11][12]. Alongside activity limits, management includes lifelong heart monitoring tailored to the individual’s risk, as well as medications like beta-blockers to help manage documented arrhythmias or symptoms [13][3].
Because Naxos disease is an autosomal recessive condition—meaning a person typically inherits one mutated gene from each parent—family health is also a priority. Siblings of a person with Naxos disease have a 25% chance of being affected (two mutated copies), a 50% chance of being a carrier (one mutated copy), and a 25% chance of inheriting neither [6]. Doctors recommend cascade screening, which involves genetic testing and clinical heart evaluations for brothers and sisters, even if they do not yet show any signs of the condition [14][15]. By identifying and monitoring affected family members early, you can implement protective strategies that prioritize long-term heart health and overall well-being [5][16].
In this guide
7 chapters
Building a Foundation: An Introduction to Naxos Disease
Learn about Naxos disease symptoms, when heart problems may develop, and how cardiology, dermatology, genetic testing, and exercise advice guide long-term care.
Recognizing Symptoms and Emergency Red Flags
Learn Naxos disease symptoms, including woolly hair, thickened palm and sole skin, palpitations, fainting, exercise limits, and emergency warning signs.
The Science of Naxos: Biology, Genetics, and Diagnosis
Learn how Naxos disease affects the heart and skin, how JUP mutations are inherited, and how ECG, cardiac MRI, and genetic testing support a diagnosis.
Protecting the Heart: Treatment and Management
Learn how Naxos disease is managed with medicines, ICDs, ablation, exercise limits, and heart-failure care to reduce dangerous rhythms and protect heart function
Dermatological Care: Managing Skin and Hair
Learn how to manage Naxos disease skin and hair changes, including palmoplantar keratoderma, painful cracks, infections, footwear, and retinoid safety guidance.
The Long View: Lifelong Monitoring and Family Care
Learn how Naxos disease follow-up uses ECGs, Holter monitors, imaging, JUP testing, exercise guidance, and family screening to support lifelong cardiac care.
Naxos Disease: A Patient Guide
Learn how Naxos disease causes woolly hair and thickened palms and soles, why heart monitoring matters, and how exercise limits and treatment protect the heart.
Common questions in this guide
What are the main signs of Naxos disease?
Why does a child with Naxos disease need heart checks if they feel well?
What activities should someone with Naxos disease avoid?
How is Naxos disease inherited, and what are the chances for siblings?
What treatment and long-term care does Naxos disease involve?
Get notified when new evidence is published on Naxos disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Naxos Disease and Related Cardio-Cutaneous Syndromes.
Protonotarios A, Asimaki A, Basso C, et al.
JACC. Advances 2025; (4(2)):101547 doi:10.1016/j.jacadv.2024.101547.
PMID: 39877668 - 2
Cardiocutaneous syndrome (Naxos disease) in a Bangladeshi boy.
Islam AM, Rahman MT, Chowdhury AH
Cardiovascular diagnosis and therapy 2016; (6(5)):462-465 doi:10.21037/cdt.2016.03.07.
PMID: 27747171 - 3
Imaging Naxos disease and related cardiocutaneous syndromes: the NAXCARE multimodality approach.
Protonotarios I, Alsergani H, Anastasakis A, et al.
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2026; doi:10.1016/j.hjc.2026.03.007.
PMID: 41936932 - 4
Combination of palmoplantar keratoderma and hair shaft anomalies, the warning signal of severe arrhythmogenic cardiomyopathy: a systematic review on genetic desmosomal diseases.
Polivka L, Bodemer C, Hadj-Rabia S
Journal of medical genetics 2016; (53(5)):289-95 doi:10.1136/jmedgenet-2015-103403.
PMID: 26399581 - 5
Naxos disease: current insights from early clinical observations to genetics and precision medicine.
Xylouri Z, Al-Sergani H, Protonotarios I, et al.
Internal and emergency medicine 2026; doi:10.1007/s11739-026-04559-9.
PMID: 42932075 - 6
Naxos disease - a narrative review.
Leopoulou M, Mattsson G, LeQuang JA, et al.
Expert review of cardiovascular therapy 2020; (18(11)):801-808 doi:10.1080/14779072.2020.1828064.
PMID: 32966140 - 7
Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility.
Vahidnezhad H, Youssefian L, Faghankhani M, et al.
Scientific reports 2020; (10(1)):21622 doi:10.1038/s41598-020-78344-9.
PMID: 33303784 - 8
Desmoplakin mutations with palmoplantar keratoderma, woolly hair and cardiomyopathy.
Pigors M, Schwieger-Briel A, Cosgarea R, et al.
Acta dermato-venereologica 2015; (95(3)):337-40 doi:10.2340/00015555-1974.
PMID: 25227139 - 9
Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy.
Lie ØH, Dejgaard LA, Saberniak J, et al.
JACC. Clinical electrophysiology 2018; (4(6)):744-753 doi:10.1016/j.jacep.2018.01.010.
PMID: 29929667 - 10
Physical Activity in Arrhythmogenic Cardiomyopathy: From Trigger to Therapeutic Dilemma.
Kayvanpour E, Meder B, Sedaghat-Hamedani F
Reviews in cardiovascular medicine 2026; (27(8)):52871 doi:10.31083/RCM52871.
PMID: 42694556 - 11
Arrhythmogenic Cardiomyopathy in 2018-2019: ARVC/ALVC or Both?
Bennett RG, Haqqani HM, Berruezo A, et al.
Heart, lung & circulation 2019; (28(1)):164-177 doi:10.1016/j.hlc.2018.10.013.
PMID: 30446243 - 12
Arrhythmogenic right ventricular cardiomyopathy and sports activity: from molecular pathways in diseased hearts to new insights into the athletic heart mimicry.
Gasperetti A, James CA, Cerrone M, et al.
European heart journal 2021; (42(13)):1231-1243 doi:10.1093/eurheartj/ehaa821.
PMID: 33200174 - 13
Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.
Akdis D, Brunckhorst C, Duru F, Saguner AM
Arrhythmia & electrophysiology review 2016; (5(2)):90-101 doi:10.15420/AER.2016.4.3.
PMID: 27617087 - 14
Genotype and cardiac outcome in patients with cardiocutaneous syndrome (Naxos disease variant: Carvajal syndrome).
Binfadel M, Aleem MU, Alhabdan M, et al.
Orphanet journal of rare diseases 2025; (20(1)):137 doi:10.1186/s13023-025-03612-8.
PMID: 40108711 - 15
[Genetic diagnostics for cardiomyopathies].
Czepluch F, Wollnik B, Hasenfuß G
Deutsche medizinische Wochenschrift (1946) 2017; (142(9)):657-664 doi:10.1055/s-0042-112183.
PMID: 28454199 - 16
Clinical and Molecular Aspects of Naxos Disease.
Protonotarios I, Asimaki A, Xylouri Z, et al.
Heart failure clinics 2022; (18(1)):89-99 doi:10.1016/j.hfc.2021.07.010.
PMID: 34776086
This page is for informational purposes only and does not constitute medical advice about Naxos disease. Your cardiologist, dermatologist, and geneticist should guide decisions about heart testing, activity, family screening, and treatment.